NeuroSense reports positive Phase 2 RoAD biomarker findings for PrimeC in Alzheimer’s disease study

Neurosense Therapeutics Ltd.

Neurosense Therapeutics Ltd.

NRSN

0.00
  • NeuroSense reported positive biomarker findings from its Phase 2 RoAD proof-of-concept trial of PrimeC in Alzheimer’s disease.
  • Results have already been presented in this announcement, based on a small exploratory dataset with limited analyzable samples.
  • Biomarker shifts broadly aligned with PrimeC’s proposed multi-target mechanism, supporting early signs of biological activity across key disease pathways.
  • The readout supports continued development, with plans to design a larger, adequately powered Alzheimer’s study to test clinical benefit.
  • Safety remained favorable in the study, with no serious adverse events reported.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606250920PR_NEWS_USPR_____IO92116) on June 25, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.